Florentis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-12-2024
- Paid Up Capital ₹ 0.82 M
as on 03-12-2024
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 6.80 M
as on 03-12-2024
- Revenue 42.51%
(FY 2022)
- Profit 44.16%
(FY 2022)
- Ebitda 353.98%
(FY 2022)
- Net Worth 9.23%
(FY 2022)
- Total Assets 6.05%
(FY 2022)
About Florentis Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.82 M.
The company has closed loans amounting to ₹6.80 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Laxman Malge, Shriram Kotkar, and Vijaykumar Pawar serve as directors at the Company.
- CIN/LLPIN
U24100PN2011PTC140877
- Company No.
140877
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Sep 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Florentis Pharmaceuticals Private Limited offer?
Florentis Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Services.
Who are the key members and board of directors at Florentis Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijaykumar Pawar  | Director | 24-Jan-2013 | Current |
| Laxman Malge | Director | 26-Sep-2011 | Current |
| Shriram Kotkar | Director | 26-Sep-2011 | Current |
Financial Performance of Florentis Pharmaceuticals.
Florentis Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 42.51% increase. The company also saw a substantial improvement in profitability, with a 44.16% increase in profit. The company's net worth moved up by a moderate rise of 9.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Florentis Pharmaceuticals?
In 2021, Florentis Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹6.80 M
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.68 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 May 2016 | State Bank Of India | ₹6.80 M | Satisfied |
How Many Employees Work at Florentis Pharmaceuticals?
Florentis Pharmaceuticals has a workforce of 7 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Florentis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Florentis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.